AnaptysBio (ANAB)
Manages Jemperli and imsidolimab royalties through GSK and Vanda partnerships.
AnaptysBio: The Royalty Waterfall Is About To Reverse
AnaptysBio is now a focused royalty management company, with its value tied primarily to Jemperli royalties from GSK. Post-spin, ANAB operates virtually with a 95% targeted EBIT margin and over $140M net cash, eliminating prior R&D burn. Jemperli royalties escalate with sales, and once the Sagard obligation is paid (expected by mid-2027), ANAB will retain high-margin, growing royalty streams.
AnaptysBio (NASDAQ:ANAB) Stock Price Up 5.3% – Still a Buy?
AnaptysBio, Inc. (NASDAQ: ANAB - Get Free Report) rose 5.3% during mid-day trading on Friday. The company traded as high as $56.54 and last traded at $57.00. 47,244 shares were traded during mid-day trading, a decline of 94% from the average daily volume of 753,749 shares. The stock had previously closed at $54.15. Analysts Set
Is AnaptysBio (ANAB) Outperforming Other Medical Stocks This Year?
Here is how AnaptysBio, Inc. (ANAB) and Electromed, Inc. (ELMD) have performed compared to their sector so far this year.
Wall Street Analysts See a 38.75% Upside in AnaptysBio (ANAB): Can the Stock Really Move This High?
The consensus price target hints at a 38.8% upside potential for AnaptysBio (ANAB). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
AnaptysBio (ANAB) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
After losing some value lately, a hammer chart pattern has been formed for AnaptysBio (ANAB), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Anaptys Announces First Quarter 2026 Financial Results and Provides Business Update
SAN DIEGO, May 12, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a company focused on managing the financial collaborations for Jemperli with GSK and imsidolimab with Vanda, today reported financial results for the first quarter ended March 31, 2026, and provided a business update.
Anaptys Appoints Chris Murphy as Chief Financial Officer and Owen Hughes to Board of Directors
SAN DIEGO, May 11, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a company focused on managing the financial collaborations for Jemperli with GSK and imsidolimab with Vanda, today announced the appointment of Christopher Murphy as Chief Financial Officer and Owen Hughes as a member of its Board of Directors.
AnaptysBio, Inc. (ANAB) is a Great Momentum Stock: Should You Buy?
Does AnaptysBio, Inc. (ANAB) have what it takes to be a top stock pick for momentum investors? Let's find out.
Are Medical Stocks Lagging AnaptysBio (ANAB) This Year?
Here is how AnaptysBio, Inc. (ANAB) and Coherus Oncology (CHRS) have performed compared to their sector so far this year.
Anaptys to Participate at the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference
SAN DIEGO, May 04, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a company focused on managing the financial collaborations for Jemperli with GSK and imsidolimab with Vanda, today announced that Daniel Faga, president and chief executive officer of Anaptys, is scheduled to participate in a fireside chat at the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference on Wednesday, May 6, 2026. The fireside chat is scheduled to begin at 1:30pm ET.
AnaptysBio, Inc. (ANAB) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
AnaptysBio (ANAB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AnaptysBio (ANAB) Surges 14.8%: Is This an Indication of Further Gains?
AnaptysBio (ANAB) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Delaware Chancery Court Rules in Favor of Anaptys by Dismissing Tesaro’s Anticipatory Breach Claim
Ruling preserves current contracted royalty rates and rejects Tesaro's request for any royalty reduction Trial to adjudicate Anaptys' contract claims and right to seek reversion of Jemperli against Tesaro/GSK is scheduled for July 14-17, 2026 SAN DIEGO, April 24, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc.
Delaware Chancery Court Rules in Favor of Anaptys by Dismissing Tesaro's Anticipatory Breach Claim
SAN DIEGO, April 24, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a company focused on managing the financial collaborations for Jemperli with GSK and imsidolimab with Vanda, today announced that the Delaware Chancery Court has dismissed Tesaro's anticipatory breach of contract claim against Anaptys. The ruling agrees with Anaptys' position that it has never repudiated the Collaboration and Exclusive License Agreement (“Collaboration Agreement”) with Tesaro, a subsidiary of GSK, governing the development and commercialization of Jemperli.
AnaptysBio (NASDAQ:ANAB) Director John Schmid Sells 20,645 Shares of Stock
AnaptysBio, Inc. (NASDAQ: ANAB - Get Free Report) Director John Schmid sold 20,645 shares of the firm's stock in a transaction dated Monday, March 30th. The stock was sold at an average price of $56.11, for a total value of $1,158,390.95. Following the completion of the transaction, the director owned 31,622 shares of the company's stock,
First Tracks Biotherapeutics, the Planned Spin-Off of Anaptys, Secures Commitments of $145 Million in Private Placement
SAN DIEGO, March 27, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB) today announced that its planned spin-off, First Tracks Biotherapeutics, Inc. (“First Tracks Bio”), and EcoR1 Capital (the “Selling Stockholder”) have entered into a purchase agreement with certain third-party investors for a $145 million private placement, before deducting placement agent fees and other expenses.
Anaptys Announces $100 Million Stock Repurchase Plan and Provides a Business Update
SAN DIEGO, March 27, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB) today announced that its Board of Directors has authorized a Stock Repurchase Plan under which the company may repurchase up to $100,000,000 of the company's outstanding common stock, par value $0.001 per share, and provided a business update.
Anaptys Board of Directors Approves Spin-Off of First Tracks Biotherapeutics
SAN DIEGO, March 27, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB) today announced that its Board of Directors has approved the previously announced spin-off of First Tracks Biotherapeutics, Inc. (“First Tracks Bio”). The new company is expected to begin “regular-way” trading on the Nasdaq Stock Market LLC (“Nasdaq”) on April 20, 2026, under the ticker symbol “TRAX.”
AnaptysBio, Inc. (ANAB) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
AnaptysBio, Inc. (ANAB) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
AnaptysBio, Inc. $ANAB Shares Sold by Citigroup Inc.
Citigroup Inc. cut its position in shares of AnaptysBio, Inc. (NASDAQ: ANAB) by 93.3% during the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 70,534 shares of the biotechnology company's stock after selling 975,954 shares during the quarter. Citigroup Inc. owned 0.25% of